No. Phototherapy does not work like a tanning bed. Phototherapy means controlled exposure to specific wavelengths of ultraviolet or visible light for a medical condition, and any darkening it produces is usually a side effect of treatment, not the goal. Narrowband UVB can darken skin through the same melanin pathway that sun exposure uses, while visible-light and laser phototherapies generally do not tan skin at all.
The distinction matters because the word phototherapy covers several unrelated technologies with opposite effects on pigment. A psoriasis patient on narrowband UVB may darken noticeably, while a jaundice newborn under blue light will not tan, and a vitiligo patient receiving excimer laser is trying to restore pigment in patches that lost it. Whether light makes you tan depends on wavelength, dose, skin type, and the condition being treated.
How light triggers melanin production
Melanin darkening begins with DNA damage. When ultraviolet photons strike keratinocytes in the epidermis, they damage DNA and trigger a cascade: p53 activation, then release of alpha-melanocyte-stimulating hormone and other signaling molecules. Those signals reach melanocytes, the pigment-producing cells, and stimulate melanogenesis, the enzymatic production of melanin.
Two pigments matter here. Eumelanin is brown-black and absorbs UV efficiently. Pheomelanin is red-yellow and less protective. The ratio between them, largely genetic, shapes how readily your skin darkens and how much UV protection that darkening provides.
Phototherapy exploits this pathway selectively. Narrowband UVB, centered near 311 to 313 nanometers, drives melanogenesis with less of the shorter-wavelength DNA damage that causes sunburn. That narrow band is why dermatologists can deliver therapeutic doses repeatedly. The skin still responds with pigment, but the dose is calibrated to the disease, not to cosmetic darkening.
A separate mechanism, immediate pigment darkening, occurs within minutes of UVA exposure. It reflects redistribution of existing melanin and does not require new pigment synthesis. This is why some people look darker right after light exposure and lighter hours later.
Plain language: phototherapy uses the same pigment switch as sunlight, but it turns that switch with a specific wavelength and a measured dose.
How much tanning different phototherapies cause
Quantifying phototherapy-induced tanning is difficult because published data rarely measure cosmetic darkening directly. What the evidence supports is a qualitative ranking by wavelength and mechanism.
Narrowband UVB, the workhorse for psoriasis and other inflammatory conditions, reliably produces tanning in most patients over a course of treatment. The effect builds gradually across weeks. Broadband UVB and PUVA, which combines a psoralen drug with UVA, produce stronger and longer-lasting pigmentation, and PUVA is associated with more pronounced tanning than narrowband UVB.
Visible blue light, used for newborn jaundice and some acne regimens, does not trigger the UV melanin pathway in any meaningful way. Excimer laser at 308 nanometers sits close to narrowband UVB and can repigment vitiligo patches, but it is targeted and does not create a general tan.
Photodynamic therapy, which combines a photosensitizing agent with light, is not a tanning modality. Some patients notice temporary darkening or uneven pigment after treatment, but this reflects inflammation and post-inflammatory change rather than melanogenesis.
The table below compares how different light-based treatments affect pigment.
| Treatment | Wavelength or type | Typical pigment effect | Mechanism |
|---|---|---|---|
| Narrowband UVB | 311–313 nm | Gradual tanning over weeks | Melanogenesis via DNA damage signaling |
| Broadband UVB | 280–320 nm | Moderate tanning, faster than NB-UVB | Same pathway, broader spectrum |
| PUVA | UVA plus psoralen | Strong, longer-lasting tan | Psoralen crosslinks DNA, amplifies melanogenesis |
| Excimer laser | 308 nm, targeted | Repigmentation of treated patches | Localized melanocyte stimulation |
| Blue-light therapy | ~415–470 nm visible | Little to no tanning | Minimal melanin pathway activation |
| Photodynamic therapy | Photosensitizer plus light | Temporary uneven darkening possible | Inflammation, not melanogenesis |
One counterintuitive detail: a tan from phototherapy is not evidence the treatment is working. Psoriasis can clear without much darkening, and darkening can occur without clinical improvement. Clinicians titrate dose to erythema thresholds, not to how brown the skin looks.
Time course: when darkening appears and fades
Phototherapy pigmentation follows a predictable arc, though individual timing varies with skin type, dose, and condition. The timeline below reflects the general pattern reported in dermatology practice.
| Phase | Typical timing | What happens |
|---|---|---|
| First sessions | Days 1–7 | Minimal visible change; possible mild pinkness |
| Early pigment | Weeks 2–4 | Faint darkening in exposed areas begins |
| Established tan | Weeks 4–8 | Noticeable darkening in many patients |
| Peak effect | Weeks 8–12 | Pigment plateaus during continued treatment |
| Treatment pause | Weeks after stopping | Pigment begins fading gradually |
| Fade-out | Months | Most phototherapy tanning resolves over weeks to months |
Newborns receiving blue-light phototherapy for jaundice do not follow this arc because the wavelength does not drive melanogenesis. Their skin color changes reflect bilirubin clearance, not tanning.
A professional caveat: phototherapy tanning fades faster than a summer tan in some patients because the doses are controlled and the total cumulative exposure is lower than habitual sunbathing. Patients who expect a durable bronze should be told otherwise.
Edge cases and who darkens differently
Skin type is the biggest variable. Fitzpatrick type I and II skin burns easily and tans minimally, so phototherapy may produce erythema before pigment. Type IV through VI skin darkens readily and may develop pronounced tanning at lower doses. This is why dosing protocols adjust for skin type.
Vitiligo is a special case. Here phototherapy aims to repigment depigmented patches, and the surrounding normal skin may tan, increasing contrast. That contrast can make vitiligo look more obvious even as treated patches improve. Clinicians often counsel patients about this expected mismatch.
Melasma and post-inflammatory hyperpigmentation can worsen with UV exposure, including therapeutic UV. Phototherapy in patients with these conditions requires caution, and visible-light protection becomes essential.
Patients with photosensitivity disorders, such as lupus or porphyria, may be harmed by phototherapy wavelengths and are generally not candidates. Medications including certain antibiotics, diuretics, and retinoids can amplify photosensitivity.
Red flag: blistering, severe pain, or fever after phototherapy requires urgent medical review. Red flag: new or changing moles in treated areas warrant dermatologic evaluation. Red flag: eye pain or vision changes after UV exposure, since unprotected eyes can be injured. Red flag: treatment in pregnancy should be discussed with the prescribing clinician, especially PUVA.
Common misconceptions about phototherapy and tanning
The most persistent misconception is that phototherapy is a medicalized tanning bed. Tanning beds typically emit UVA and some UVB at doses chosen for cosmetic effect. Phototherapy doses are chosen to treat disease, are often lower, and use narrower spectra. The overlap is real but partial.
A second misconception is that a tan protects you from phototherapy side effects. It does not. Pigment offers some UV absorption, but it does not eliminate burning risk or make overtreatment safe.
A third is that all phototherapy darkens skin. Blue-light jaundice therapy and many visible-light acne treatments do not. Patients who expect a tan from these modalities will be disappointed.
A fourth is that phototherapy tanning is harmless because it is medical. Cumulative UV exposure carries skin cancer risk over time, particularly with PUVA, which is associated with increased squamous cell carcinoma risk. That is why courses are limited and monitored.
Finally, some patients believe phototherapy replaces the need for sun protection. It does not. Sun protection remains necessary during and after treatment.
Practical steps if you are starting phototherapy
Ask what wavelength and dose you are receiving. Narrowband UVB, PUVA, excimer laser, and blue light have different pigment and risk profiles.
Protect unaffected areas. Shield the face, genitals, and any areas not being treated unless your clinician directs otherwise. Goggles are standard for UV therapies.
Do not add tanning beds or solarium sessions. Combining sources raises cumulative UV dose without therapeutic benefit.
Track your skin response between sessions. Note redness, tenderness, and darkening, and report changes promptly so doses can be adjusted.
Use broad-spectrum sunscreen on exposed skin outside treatment, and follow your clinician's instructions about which products to avoid before sessions. Some topical treatments increase light sensitivity.
Reconcile thresholds explicitly: a session that produces faint pinkness is often the target, not visible tanning. If your goal is cosmetic darkening, phototherapy is the wrong tool, and if your goal is treatment, pigment is a side effect to discuss rather than a measure of success.
Limitations of what the evidence can tell you
Much of the tanning effect of phototherapy is described in clinical observation rather than measured in controlled studies. Few trials report cosmetic darkening as an endpoint. Most report disease severity scores, erythema, and adverse events.
Wavelength and dose vary across protocols and devices, so results from one clinic may not transfer to another. Skin type, age, medication use, and the underlying condition all modify pigment response.
Long-term pigment outcomes and skin cancer risk depend on cumulative dose over years, and the evidence base for newer devices is thinner than for established narrowband UVB and PUVA.
The honest answer to whether phototherapy makes you tan is that some forms can, through the same melanin pathway as sunlight, but it is not a tanning method, not all phototherapy darkens skin, and darkening is a side effect rather than a goal. Patients should judge treatment by clinical response and safety monitoring, not by how brown they become.